Why join us?
FogPharma is a biopharmaceutical company pioneering the discovery and development of Helicon™ therapeutics, which are peptides capable of efficient cell entry and modulation of both protein-protein and protein-DNA interactions. Through Helicon therapeutics, FogPharma is poised to revolutionize the medical possibilities for patients by precisely drugging intracellular targets long understood to be significant drivers of disease but never before drugged due to the limitations of existing drug modalities to act within the cell.
FOG-001, the company’s first-in-class TCF-blocking β-catenin inhibitor, is being evaluated in a Phase 1/2 study for patients with advanced solid tumors, including colorectal cancer. FogPharma is fully leveraging the unprecedented potential Helicons present by deploying proprietary, custom-built machine learning and computational methods as part of its discovery and development process. FogPharma has raised more than $500 million to date from leading life sciences investors. FogPharma is headquartered in Cambridge, Mass.
What’s the opportunity?
FogPharma has an exciting new opportunity for a Sr. Scientist, Discovery DMPK to play a key role in advancing our transformational new modality, Helicon™ degraders, to clinical development. As part of the Discovery Sciences group, you will serve as the DMPK representative to discovery project teams and help to guide the progression of Helicons from hit-to-lead through initiation of IND-enabling studies.
-
- Represent the Discovery DMPK functional area on multidisciplinary project teams and provide expert scientific and strategic input.
- Analyze, interpret, report and present DMPK/ADME data in written summaries and at internal meetings.
- Design, execute and troubleshoot DMPK studies with CROs to support internal discovery projects.
- Identify and maintain close relationships with CROs that conduct in vitro and in vivo DMPK studies specific to out needs.
- Propose and test mechanistic hypotheses to increase our understanding of the pharmacokinetic characteristics of Helicons.
- Build and maintain strong partnerships with members of the Medicinal Chemistry, Pharmacology, Toxicology, Data Science and De Novo Discovery groups.
- Collaborate with medicinal chemists and data scientists to incorporate DMPK principles into compound design.
- Work closely with the Data Science team to develop ML/AI models that accelerate optimization of the DMPK behavior of Helicons.
- Contribute to DMPK sections of regulatory documents in support of clinical development (IND).
What you’ll need to be successful:
- PhD in Biochemistry, Drug Metabolism, Pharmacokinetics, Pharmacology or a related discipline with at least 5 years of biotech/pharmaceutical drug discovery experience, or MS with 8-10 years of experience.
- Prior experience as a core DMPK project team representative on a multifunctional drug discovery project team is required.
- Expertise in managing CRO relationships is essential.
- Experience in the field of targeted protein degradation is advantageous.
- Strong critical thinking and scientific skills with a demonstrated ability to analyze, interpret, and clearly communicate complex results.
- Excellent communication, organization, and team skills.
- Comfort operating in a dynamic, fast-paced, and highly collaborative work environment.
- Ability to work on-site and attend in-person meetings.
Core Values
FogPharma is a team of passionate pioneers who are trailblazing the future of precision medicine with the aim of making a meaningful difference in the lives of patients. The company is committed to promoting an inspiring and flourishing working environment for all employees across the business, in all departments, and driving innovation for patient benefit.
- Creative. We are creating a whole new class of medicine requiring creativity to solve challenges as they arise, which we have successfully done since the inception of the company.
- Patient-focused. We are deeply focused on patient outcomes, and all energy in the company is focused on science as it translates to patient impact.
- Execution-oriented. As we begin clinical development and large-scale manufacturing, the team is balancing creativity and nimbleness with relentless, rigorous and flawless execution.
- Humble. We fully appreciate that science and technology and policy are in flux, and we balance deep experience with humility to ask fundamental questions and seek newly available solutions.
As an equal opportunity employer, Fog values diversity and welcomes applicants of all backgrounds and experiences. All qualified applicants will receive consideration for employment without discrimination on the basis of race, color, religion, sex, sexual orientation, gender identity, national origin, protected veteran status, disability, or any other factors prohibited by law.
30 Acorn Park Drive | Cambridge, MA 02140 | www.fogpharma.com